Aug 19, 2019
HedgePath Pharmaceuticals Announces Name Change to INHIBITOR Therapeutics, Inc. and Ticker Symbol Change to "INTI" Effective August 20, 2019
May 29, 2019
HedgePath Pharmaceuticals Announces Notice of Allowance with Additional Claims Governing the Use of SUBA®-Itraconazole for the Treatment of Lung Cancer
May 06, 2019
HedgePath Pharmaceuticals Announces Notice of Allowability of U.S. Patent Application Regarding Treatment of Prostate Cancer
Apr 15, 2019
W. Mark Watson Elected as Chairman of the Board of HedgePath Pharmaceuticals
Mar 07, 2019
HedgePath Pharmaceuticals Provides Corporate Update for the Fourth Quarter and Year End 2018
Oct 11, 2018
HedgePath Pharmaceuticals to Present at the 2018 BioFlorida Annual Conference
Oct 09, 2018
HedgePath Pharmaceuticals' Pathway for Filing SUBA BCCNS NDA Clarified in Meeting with FDA
Jul 19, 2018
HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole
Jun 05, 2018
HedgePath Pharmaceuticals Granted Meeting with FDA to Discuss SUBA BCCNS Trial Data and Regulatory Pathway
May 21, 2018
HedgePath Pharmaceuticals Announces Additional Expanded Patent Coverage
May 14, 2018
HedgePath Pharmaceuticals Announces Expanded Patent Coverage
Jan 11, 2018
HedgePath Pharmaceuticals Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs
Oct 30, 2017
HedgePath Pharmaceuticals Completes Enrollment for its Phase 2(b) Trial in BCCNS and Provides Trial Update
Jul 25, 2017
HedgePath Pharmaceuticals Receives Clarity From FDA Regarding Pathway to Potential Regulatory Submission
May 30, 2017
HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update